-
Innovation Ranking
NewInnovation Ranking – Daewoong Pharmaceutical Co Ltd
Daewoong Pharmaceutical Co Ltd (Daewoong Pharmaceutical), a subsidiary of Daewoong Co Ltd, is a manufacturer and distributor of prescription drugs in South Korea. It offers prescription drugs, quasi drugs, healthcare products and APIs. The company produces products in the form of tablets, capsules, ointments, injections, liquids, and sprays. It offers products for conditions such as bone and joint diseases, cardiovascular diseases, central nervous system diseases, circulatory system, dermatological, gastrointestinal, and respiratory system remedies. It also carries out the development and...
-
Company Insights
Innovation and Patenting activity of Daewoong Co Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Daewoong Co Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Company Insights
Innovation and Patenting activity of Daewoong Pharmaceutical Co Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Daewoong Pharmaceutical Co Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DWP-708 in Skin Rash
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DWP-708 in Skin Rash report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DWP-708 in Skin Rash Drug Details: DWP-708 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Fexuprazan in Helicobacter pylori Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Fexuprazan in Helicobacter pylori Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Fexuprazan in Helicobacter pylori Infections Drug Details: Fexuprazan (Fexuprazan Hydrochloride, Fexuclu,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bersiporocin in Idiopathic Pulmonary Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bersiporocin in Idiopathic Pulmonary Fibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bersiporocin in Idiopathic Pulmonary Fibrosis Drug Details: Bersiporocin (DWN-12088, DWJ-209) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TIDAL-01 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TIDAL-01 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TIDAL-01...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Regorafenib in Soft Tissue Sarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Regorafenib in Soft Tissue Sarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Regorafenib in Soft Tissue Sarcoma Drug Details: Regorafenib (BAY 73-4506,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ABBV-637 in Transitional Cell Cancer (Urothelial Cell Cancer)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ABBV-637 in Transitional Cell Cancer (Urothelial Cell Cancer) Drug Details: ABBV-637 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dexmedetomidine in Opium (Opioid) Addiction
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Dexmedetomidine in Opium (Opioid) Addiction Drug Details: Dexmedetomidine (Igalmi) is an imidazole derivate and active...